ASCO GUIDELINES Bundle

Antiemetics (CINV)

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/856867

Contents of this Issue

Navigation

Page 6 of 17

7 Table 1. Emetic Risk of Single Intravenous Antineoplastic Agents in Adults Risk Level Agent High (>90%) Anthracycline/cyclophosphamide combination Carmustine Cisplatin Cyclophosphamide >1,500 mg/m² Dacarbazine Mechlorethamine Streptozocin Moderate (30%–90%) Alemtuzumab Azacitidine Bendamustine Carboplatin Clofarabine Cyclophosphamide <1,500 mg/m² Cytarabine >1,000 mg/m² Daunorubicin Doxorubicin Epirubicin Idarubicin Ifosfamide Irinotecan Irinotecan liposomal injection Oxaliplatin Romidepsin Temozolomide a iotepa b Trabectedin Low (10%–30%) Aflibercept Atezolizumab Belinostat Blinatumomab Bortezomib Brentuximab Cabazitaxel Carfilzomib Catumaxumab Cetuximab Cytarabine ≤1,000 mg/m² Docetaxel Elotuzumab Eribulin Etoposide Fluorouracil Gemcitabine Ipilimumab Ixabepilone Methotrexate Mitomycin Mitoxantrone Nab-paclitaxel Necitumumab Paclitaxel Panitumumab Pemetrexed Peg ylated liposomal doxorubicin Pertuzumab Temsirolimus Topotecan Trastuzumab-emtansine Vinflunine Minimal (<10%) Bevacizumab Bleomycin Busulfan 2-Chlorodeoxyadenosine Cladribine Daratumumab Fludarabine Nivolumab Obinutuzumab Ofatumumab Pembrolizumab Pixantrone Pralatrexate Ramucirumab Rituximab Trastuzumab Vinblastine Vincristine Vinorelbine a No direct evidence found for intravenous temozolomide. Since all sources indicate a similar safety profile to the oral formulation, the classification was based on oral temozolomide. b Classification refers to individual evidence from pediatric trials.

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Antiemetics (CINV)